Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

ally significant and clinically meaningful effect on both the primary endpoint of change in percent predicted FVC and secondary endpoints of progression-free survival and categorical change in percent predicted FVC. While CAPACITY 1 did not achieve statistical significance on the primary endpoint, the results were generally consistent with and supportive of CAPACITY 2. Further, the treatment effect observed in the CAPACITY studies was generally consistent with that observed in the Phase 3 study of pirfenidone in IPF patients conducted by Shionogi & Co. Ltd. in Japan."

Dr. Roland du Bois, Professor of Medicine at National Jewish Health, Denver, Colo., and CAPACITY co-chair also commented on the CAPACITY results. "When taken in the context of the urgent unmet medical need for new medicines to treat IPF patients, the collective efficacy and safety data from the two CAPACITY studies, corroborated by a similar study in Japan, make a case for the use of pirfenidone in this disease setting."

Primary Efficacy Endpoint Results

The primary endpoint of both CAPACITY studies was change in percent predicted Forced Vital Capacity (FVC) after 72 weeks of treatment, evaluated with a nonparametric rank ANCOVA. In the CAPACITY 2 study, the primary endpoint was met (p=0.001). In CAPACITY 1, the primary endpoint was not met (p=0.501). An exploratory analysis of pooled primary endpoint data from both studies using the pre-specified primary endpoint test statistic from a nonparametric rank ANCOVA resulted in a P value of 0.005.

A pre-specified repeated measures analysis of the primary endpoint was used to obtain a least squares mean estimate (LS mean) of the magnitude of the treatment effect. The LS mean change in percent predicted FVC at Week 72 was -6.5% and -9.6% in the pirfenidone and placebo groups, respectively, in CAPACITY 2, and -6.5% and -7.2%, respectively, in CAPACITY 1. This represents
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... 2014   NuVascular Technologies, Inc. is ... medical devices that help millions. ... cutting-edge nanotechnology that would target serious conditions such ... The platform technology was developed over a ... in funding obtained from National Institutes of Health. ...
(Date:10/16/2014)... Oct. 16, 2014 Ninety percent of children ... relapsed multiple times or failed to respond to standard ... cellular therapy, CTL019, developed at the Perelman School of ... today in The New England Journal ... builds on preliminary findings presented at the American Society ...
(Date:10/16/2014)... Oct. 16, 2014   Reliant Renal Care, Inc. ... Home Choice TM Training Center at 650 ... passing all regulatory requirements without any deficiencies, our state-of- ... admitting patients. The Center focuses on the unique needs ... in the comfort of their home. The open-access facility ...
Breaking Medicine Technology:Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 2Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6A New Choice For Dialysis Patients In Bessemer 2
(Date:10/18/2014)... Dwight D. Im, M.D., FACOG, Director ... The National Institute of Robotic Surgery at Mercy ... world to successfully perform a minimally-invasive hysterectomy via ... Driver, developed by Intuitive Surgical, Inc. (ISRG). , ... and Drug Administration (FDA) clearance for use in ...
(Date:10/18/2014)... Recently, BamboofloorChina.com, one of the most distinguished bamboo ... assortment of bamboo floorings to its website. For ... worldwide clients now, up to 29 percent off. , ... for sale now; most of the company’s experts have been ... than 100 different kinds of elegant bamboo products on its ...
(Date:10/18/2014)... of Neuropsychopharmacology (ECNP) is pleased to announce that the ... Swaab, for his book, We are our Brains: From ... Media Award recognises outstanding contributions to destigmatising disorders of ... € 5,000. , The ECNP Media Award was established ... better understanding of the complexity and impact of disorders ...
(Date:10/18/2014)... One major trend upcoming in this ... which are making efforts to encourage people to donate ... organ donation process more transparent and easy. , Analysts ... to grow at a CAGR of 16.85 percent over ... the major drivers in the market is an increase ...
(Date:10/18/2014)... For the second time in less than a month, ... facing US businesses. On September 23rd, the warning ... employees. And now, according to this Reuters report , ... for US businesses about possible cyber espionage attacks by a ... high-value information.” , “With the constant stream of headlines ...
Breaking Medicine News(10 mins):Health News:National Recognized Gynecologic Oncologist Dr. Dwight Im World's First to Perform Surgery Using New FDA Cleared Single Site Wristed Needle Driver Technology 2Health News:National Recognized Gynecologic Oncologist Dr. Dwight Im World's First to Perform Surgery Using New FDA Cleared Single Site Wristed Needle Driver Technology 3Health News:Brand New Bamboo Floorings Now Unveiled By BamboofloorChina.com, A Distinguished Supplier In The Market 2Health News:Dick Swaab wins the 2014 ECNP Media Award 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 3Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 4Health News:Another FBI Cyber Attack Warning for US Businesses 2Health News:Another FBI Cyber Attack Warning for US Businesses 3Health News:Another FBI Cyber Attack Warning for US Businesses 4
... Phase II for melanoma, to begin Phase II for breast ... cancer ... today at 9:00 a.m. EDT -, BRANFORD, Conn., April 22 CuraGen Corporation,(Nasdaq: ... the quarter ended March 31, 2008, CuraGen reported a net loss,of $6.8 million, or ...
... China, April 22 /Xinhua-PRNewswire Simcere Pharmaceutical,Group (NYSE: ... of,branded generic pharmaceuticals and manufacturer of the ... announced that it has,signed a definitive agreement ... Wuhu,Zhong Ren Pharmaceutical Co. Ltd. for a ...
... for the Service,Employees International Union claimed in an ... other acts of intimidation against,officers, directors and staff ... nothing more than "free speech.", A temporary ... Court Commission Jon Rantzman remains in effect today. ...
... treatment with drug 5-fluorouracil, study says , , MONDAY, April ... used chemotherapy drug causes memory problems and other cognitive ... brain," a new study found. , Up to 50 ... problems a year after chemotherapy treatment ended, according to ...
... DANVILLE, PA. Hearing repeated stories of suffering from ... workers, a new Geisinger-led study suggests. , In a ... Social Work Practice, Geisinger Senior Investigator Joseph Boscarino, PhD, ... and secondary trauma among 236 New York City social ...
... Appointed to Board ... of Directors, CINCINNATI, April 21, 2008 ... (Jack) F. Smith (70),will retire from the board following P&G,s April board meeting ... to:, http://www.prnewswire.com/mnr/pg/32757/ Mr. Smith has served on the board since 1995 ...
Cached Medicine News:Health News:CuraGen Reports First Quarter 2008 Financial Results 2Health News:CuraGen Reports First Quarter 2008 Financial Results 3Health News:CuraGen Reports First Quarter 2008 Financial Results 4Health News:CuraGen Reports First Quarter 2008 Financial Results 5Health News:CuraGen Reports First Quarter 2008 Financial Results 6Health News:Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd. 2Health News:SEIU Claims Right of 'Free Speech' to Stalk, Harass, and Threaten Registered Nurses According to the California Nurses Association 2Health News:Common Chemotherapy Drug Linked to Memory Problems 2Health News:Common Chemotherapy Drug Linked to Memory Problems 3Health News:Procter & Gamble Announces Board Changes 2
Button shape tip, round serrated handle, dull finish, overall length 130 mm....
... EX is a rigid gas lens with ... specific characteristics as hard contact lens, it ... excellent performance against astigmatism. The key feature ... combination of fluoromethacrylate, Siloxanylmethacrylate and methacrylic acid, ...
Magniclear is the first presbyopic lens to combine the clear distance optics of a spherical lens, the intermediate visual performance of a multifocal and the predictably crisp, near power of a bifoca...
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Medicine Products: